M&T Bank’s Emergent Biosolutions EBS Stock Holding History

M&T Bank’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,003	Closed	-$412K	–	1652
2022 Q1	$412K	Sell	10,003 -5,204	-34%	-$230K	﹤0.01%	1072
2021 Q4	$661K	Buy	15,207 +443	+3%	+$20K	﹤0.01%	905
2021 Q3	$739K	Sell	14,764 -280	-2%	-$17K	﹤0.01%	848
2021 Q2	$948K	Sell	15,044 -3,723	-20%	-$239K	﹤0.01%	776
2021 Q1	$1.74M	Buy	18,767 +35	+0.2%	+$3.58K	0.01%	593
2020 Q4	$1.68M	Buy	18,732 +3,220	+21%	+$296K	0.01%	616
2020 Q3	$1.6M	Sell	15,512 -3,670	-19%	-$396K	0.01%	582
2020 Q2	$1.52M	Sell	19,182 -4,739	-20%	-$353K	0.01%	582
2020 Q1	$1.38M	Buy	23,921 +208	+0.9%	+$12K	0.01%	606
2019 Q4	$1.28M	Sell	23,713 -2,481	-9%	-$135K	0.01%	543
2019 Q3	$1.37M	Buy	26,194 +3,325	+15%	+$155K	0.01%	619
2019 Q2	$1.1M	Sell	22,869 -8,336	-27%	-$399K	0.01%	706
2019 Q1	$1.58M	Buy	31,205 +651	+2%	+$38.4K	0.01%	587
2018 Q4	$1.81M	Buy	30,554 +6,323	+26%	+$408K	0.01%	517
2018 Q3	$1.59M	Sell	24,231 -220	-0.9%	-$12.8K	0.01%	606
2018 Q2	$1.23M	Sell	24,451 -2,020	-8%	-$105K	0.01%	696
2018 Q1	$1.39M	Buy	26,471 +3,379	+15%	+$168K	0.01%	656
2017 Q4	$1.07M	Buy	23,092 +4,350	+23%	+$183K	0.01%	744
2017 Q3	$758K	Hold	18,742	–	–	﹤0.01%	833
2017 Q2	$635K	Buy	18,742 +271	+1%	+$8.37K	﹤0.01%	898
2017 Q1	$536K	Buy	18,471 +1,566	+9%	+$47.7K	﹤0.01%	969
2016 Q4	$555K	Buy	16,905 +2,903	+21%	+$87K	﹤0.01%	1014
2016 Q3	$441K	Buy	14,002 +1,987	+17%	+$57.7K	﹤0.01%	1104
2016 Q2	$338K	Buy	12,015 +3,611	+43%	+$142K	﹤0.01%	1187
2016 Q1	$305K	Sell	8,404 -8,781	-51%	-$310K	﹤0.01%	1263
2015 Q4	$688K	Sell	17,185 -1,804	-10%	-$62.9K	﹤0.01%	947
2015 Q3	$541K	Sell	18,989 -1,681	-8%	-$55.4K	﹤0.01%	1031
2015 Q2	$681K	Buy	+20,670	New	+$641K	﹤0.01%	1050

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

M&T Bank's EBS Position: Q2 2022 in Review

M&T Bank sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 10,003 shares — an estimated $412K sold.

M&T Bank first reported a position in EBS in Q2 2015 and held it in 28 quarters. The position peaked at $1.81M in Q4 2018. 231 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

M&T Bank reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
M&T Bank sold 10,003 Emergent Biosolutions shares in Q2 2022, an estimated $412K.
M&T Bank first reported a position in Emergent Biosolutions in Q2 2015 and held it in 28 quarters.
M&T Bank's Emergent Biosolutions position peaked at $1.81M in Q4 2018.
231 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on M&T Bank's 13F filing for Q2 2022, filed 5 Aug 2022.